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Abstract
Background: Evidence of predictive power of various fatty acids on the risk of metabolic syndrome was scanty.
We evaluated the role of various fatty acids, including saturated fat, monounsaturated fat, transfat, n-6 fatty acid,
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), for the risk of the metabolic syndrome in Taiwan.
Results: A nested case-control study based on 1000 cases of metabolic syndrome and 1:1 matched control
subjects. For saturated fat, monounsaturated fat and transfat, the higher the concentration the higher the risk for
metabolic syndrome: participants in the highest quintile had a 2.22-fold (95% confidence interval [CI], 1.66 to 2.97)
higher risk of metabolic syndrome. In addition, the participants in higher EPA quintiles were less likely to have the
risk of metabolic syndrome (adjusted risk, 0.46 [0.34 to 0.61] for the fifth quintile). Participants in the highest risk
group (low EPA and high transfat) had a 2.36-fold higher risk of metabolic syndrome (95% CI, 1.38 to 4.03),
compared with those in the lowest risk group (high EPA and low transfat). For prediction power, the area under
ROC curves increased from 0.926 in the baseline model to 0.928 after adding fatty acids. The net reclassification
improvement for metabolic syndrome risk was substantial for saturated fat (2.1%, P = 0.05).
Conclusions: Plasma fatty acid components improved the prediction of the metabolic syndrome risk in Taiwan.
Introduction
Identifying dietary factors for the development of type 2
diabetes and metabolic syndrome is essential for primary
prevention [1,2]. Dietary intake habits of fatty acids,
including consumption of foods with high saturated fat
and high transfat contents, are associated with insulin
resistance and hyperlipidemia [3]. In addition, transfat
has frequently been reported to be risk factors for
cardiovascular diseases [4,5], and the evidence for
monounsaturated fats was inconclusive [6]. In contrast,
marine-derived fatty acids, such as eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA) are inversely
related to type 2 diabetes due to reduced inflammation
and increased insulin sensitivity [7]. However, although
there have been many studies about the association of
specific fatty acids and the risk of cardiovascular dis-
e a s e s ,t h e r eh a v eo n l yb e e nal i m i t e dn u m b e ro fi n t e -
grated comparison studies. Previous studies on fatty
acids have focused on specific fatty acids only, without
considering all of the fatty acids together [8-10]. In addi-
tion, the performance measures of each fatty acid have
not been evaluated extensively, and clinical situations
not considered simultaneously. Therefore, the aim of
this study was to evaluate the specific role of various
fatty acids, including saturated fat, monounsaturated fat,
t r a n s f a t ,n - 6f a t t ya c i d ,E P Aa n dD H A ,f o rt h er i s ko f
the metabolic syndrome among ethnic Chinese adults in
Taiwan. In addition, we evaluated the performance mea-
sures of these fatty acids and investigated the joint effect
of two fatty acids together to test the prediction for the
risk of metabolic syndrome.
Results
Table 1 presents the clinical, biochemical distribution,
and fatty acid profiles of the study participants, specified
by metabolic syndrome status. Compared with the con-
trol subjects, the case participants with metabolic syn-
drome were more likely to have a higher blood pressure,
body mass index, waist circumference, total and LDL
cholesterol, triglycerides, fasting glucose, uric acid,
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l e v e l .T h ec a s ep a t i e n t sw e r em o r el i k e l yt os m o k ea n d
less likely to exercise regularly. Due to the matched fac-
tors, age and gender were similar between the two
groups. With regards to the absolute amount of fatty
acids, participants with metabolic syndrome were more
likely to have higher levels of saturated fatty acid, n-6
fatty acid, polyunsaturated fatty acid, and transfat.
However, after adjusting for total fatty acid intake, the
case participants with metabolic syndrome tended to
have higher levels of saturated fat, monounsaturated
fatty acid, and lower n-6 fatty acid, n-3 fatty acid, mar-
ine fatty acid, polyunsaturated fatty acid, and EPA and
DHA concentrations compared with the control sub-
jects. The age and gender adjusted Spearman correlation
coefficients between the biochemical and fatty acid
Table 1 Basic characteristics and fatty acid distributions of the study participants, specified by metabolic
syndrome status
No metabolic syndrome n = 986 Metabolic syndrome, n = 1000
Freq % Freq %
Gender 0.67
Women 348 35.3 362 36.2
Men 638 64.7 638 63.8
Smoking 139 14.1 185 18.5 0.008
Drinking 575 58.3 571 57.1 0.58
Exercise 549 55.7 502 50.2 0.014
Mean Std Dev Mean Std Dev P
Age, yr 54.4 10.8 54.9 10.7 0.32
Systolic blood pressure, mmHg 122.7 14.8 133.2 14.8 < .0001
Diastolic blood pressure, mmHg 72.9 9.8 79.2 10.2 < .0001
Body mass index, kg/m
2 22.8 2.3 27.1 3.0 < .0001
Waist, cm 79.2 6.4 94.3 7.0 < .0001
Total cholesterol, mg/dL 202.7 36.4 206.8 36.8 0.012
Triglycerides, mg/dL 115.4 74.0 178.3 104.5 < .0001
HDL cholesterol, mg/dL 43.1 9.7 38.5 7.0 < .0001
LDL cholesterol, mg/dL 116.3 31.5 124.9 32.7 < .0001
Uric acid, mg/dL 6.2 1.5 6.6 1.6 < .0001
Fasting glucose, mg/dL 93.1 22.2 105.0 28.1 < .0001
Fatty acid, mg/dL
Saturated fat 1713.0 512.9 1982.9 682.8 < .0001
MUFA 616.3 246.5 728.9 285.9 < .0001
Trans fatty acid 267.4 106.7 322.3 158.9 < .0001
PUFA 1488.2 347.9 1542.7 361.7 0.0006
N-6 fatty acids 1297.4 313.4 1350.0 325.1 0.0003
N-3 fatty acids 190.8 60.8 192.7 58.9 0.48
Marine fatty acids 132.7 52.4 131.6 50.3 0.64
EPA 21.5 14.5 20.3 12.5 0.06
DHA 111.2 42.7 111.3 41.9 0.97
Total fat amount 40.8 10.7 45.8 13.2 < .0001
Fatty acid, % total fatty acids
Saturated fat 41.8 4.4 43.0 4.6 < .0001
MUFA 14.8 2.6 15.7 2.6 < .0001
Trans fatty acid 6.52 1.84 6.95 2.00 < .0001
PUFA 36.8 4.7 34.4 4.8 < .0001
N-6 fatty acids 32.1 4.2 30.0 4.2 < .0001
N-3 fatty acids 4.76 1.37 4.34 1.21 < .0001
Marine fatty acids 3.32 1.23 2.97 1.09 < .0001
EPA 0.54 0.37 0.46 0.28 < .0001
DHA 2.78 0.99 2.51 0.91 < .0001
Abbreviations: MUFA: monounsaturated fatty acid; PUFA: polyunsaturated fatty acid; EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid.
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The correlations for absolute amount and relative per-
centage of fatty acids were different: for the absolute
amount of fatty acids, most coefficients were positive for
triglycerides, ranging from 0.11 for marine fatty acid to
0.74. However, the coefficients changed modestly for
total fat percentage: marine fatty acid, EPA and DHA
were inversely related to waist circumference (ranging
from -0.10 to -0.16) and triglycerides (-0.24 to -0.29),
and positively related to HDL cholesterol (0.16 to 0.21).
Other clinical variables, including blood pressure, total
cholesterol, LDL cholesterol, uric acid, fasting glucose,
and glomerular filtration rate, were not significantly
associated with EPA and DHA.
According to the quintiles of various fatty acids,
including saturated fat, monounsaturated fat, transfat,
n-6 fatty acid, and EPA and DHA concentrations in the
control subjects, we examined the adjusted odds ratios
and 95% confidence intervals (CI), and tested for trend
for the risk of metabolic syndrome (Table 2). For satu-
rated fat, monounsaturated fat and transfat, the higher
the concentration, the higher the risk for the metabolic
syndrome. Compared with those in lower saturated fat
quintiles, participants in the highest quintile had a 2.22-
fold increased risk (95% confidence interval [CI], 1.66 to
2.97, P < 0.0001) of having the metabolic syndrome.
The effects persisted after multiple adjustments. Similar
positive associations existed for monounsaturated fat
and transfat: the adjusted risks in the participants in the
fifth quintile were 1.89 (95% CI, 1.18 to 3.01) for mono-
unsaturated fat and 1.53 (95% CI, 0.99 to 2.35, test for
trend, P=0.002) for transfat. However, an inverse asso-
ciation was found for n-6 fatty acid, EPA and DHA.
Compared with those in the lowest EPA quintile, the
participants in higher EPA quintiles were less likely to
have a risk of metabolic syndrome (age and gender
adjusted risk, 0.62 [95% CI, 0.47 to 0.81] for the second,
0.60 [0.46 to 0.79] for the third, 0.60 [0.45 to 0.78] for
the fourth, and 0.46 [0.34 to 0.61] for the fifth quintile,
test for trend, P < 0.0001). The protective effects of EPA
were still persistent after multiple adjustments. Similar
patterns were found for DHA levels. Compared with the
first DHA quintile, the multivariate adjusted risks for
consequent quintiles were 0.87 (0.58 to 1.29), 0.65 (0.43
to 1.00), 0.51 (0.33 to 0.78) and 0.54 (0.35 to 0.84),
respectively. The estimated risk for continuous variables,
specified by concentration as a unit or by one standard
deviation unit, showed various standardized coefficients,
the absolute values ranging from 0.15 for saturated fat
to 0.29 for n-6 fatty acid (Additional file 1 Table S2).
To test the performance measures of different fatty
acid profiles, we estimated the area under the receiver
operative characteristics (ROC) curves (AUCs) in the
baseline model, and tested the incremental values after
adding one fatty acid (Table 3). If treated as quintile
values, the AUC increased from 0.926 in the baseline
model to 0.928 in the additional n-6 fatty acid model (P
for difference among 7 models, 0.009). The reclassifica-
tion tables with and without EPA and transfat are
shown in Additional file 1 Table S3, and the perfor-
mance measure values are listed in Table 4. The net
reclassification improvement was substantial for satu-
rated fat (2.1%, 95% CI, 0.0% to 4.2%, P = 0.05), and the
integrated discriminative improvement values for fatty
acids were significant, ranging from 0.2% for saturated
f a ta n dD H At o0 . 7 %f o rm o n o u n s a t u r a t e df a ta n dn - 6
fatty acid (all P < 0.05).
In mutually adjusted models for two fatty acids, most
fatty acids remained significant and strong risk factors
for metabolic syndrome (Table 5). For example, the
adjusted odds ratio of the highest EPA quintile was 0.55
(95% CI, 0.35 to 0.86) and that of the highest saturated
fat quintile 1.56 (95% CI, 1.00 to 2.45). In joint analyses,
participants in the highest risk group (low EPA and high
transfat) had a 2.4-fold higher risk of metabolic
syndrome (adjusted odds ratio, 2.36, 95% CI, 1.38 to
4.03, P = 0.002), compared with those in the lowest risk
group (high EPA and low transfat) (Figure 1).
Discussion
Our study clearly demonstrated that plasma fatty acid
components improved the prediction of the risk of the
metabolic syndrome among ethnic Chinese adults in
Taiwan. Significant simultaneous effects and joint addi-
tive effects were also shown for these fatty acids. Addi-
tional information on fatty acids is necessary to predict
the status of metabolic syndrome in adult populations,
implied by a good performance measure. Extrapolations
to the clinical purpose of these findings were feasible for
management of metabolic syndrome in primary preven-
tion setting. Because of high prevalence of metabolic
syndrome worldwide, our findings would be applied in
clinical setting.
Our findings were consistent with previous studies.
Both n-6 and n-3 polyunsaturated fatty acids have
been associated with lower cardiovascular risk [11,12].
Dietary fat quality has been reported to influence the
activity of enzymes involved in the desaturation of
fatty acids in the body, and data from metabolic and
clinical studies support recommendations to replace
saturated and trans fat with unsaturated fat in the pre-
vention of cardiovascular disease. Our data support
that saturated fat, monounsaturated fat, and transfat
are significantly associated with the risk of metabolic
syndrome. For the protective role of fatty acids, marine
fatty acids, especially EPA and DHA, have been shown
t op l a yap r o t e c t i v er o l ei nt h er i s ko fm e t a b o l i c
syndrome [12,13].
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study participants
Q1 Q2 Q3 Q4 Q5 P, Trend
Saturated fat, % total fatty acids
Range < 38.0 38.0-40.1 40.1-42.5 42.5-45.7 > = 45.7
Median 36.6 39.2 41.2 44.1 48.3
Control 195 196 196 197 195 < .0001
Cases 127 168 221 201 281
Odds ratio OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Model 1 1 1.31 0.97 1.78 1.75 1.30 2.34 1.57 1.16 2.11 2.22 1.66 2.97 < .0001
Model 2 1 1.05 0.67 1.64 1.48 0.97 2.28 1.20 0.78 1.84 1.94 1.27 2.96 0.002
Model 3 1 1.03 0.65 1.63 1.33 0.85 2.06 1.03 0.66 1.60 1.68 1.08 2.62 0.025
MUFA, % total fatty acids
Range < 12.6 12.6-14.1 14.1-15.4 15.4-16.9 > = 16.9
Median 11.5 13.5 14.7 16.2 18.2
Control 195 196 197 196 195 < .0001
Cases 117 150 161 256 314
Model 1 1 1.27 0.93 1.74 1.38 1.01 1.89 2.22 1.65 2.99 2.76 2.06 3.70 < .0001
Model 2 1 1.26 0.80 1.99 1.01 0.64 1.59 1.89 1.22 2.91 2.12 1.37 3.26 < .0001
Model 3 1 1.14 0.71 1.83 0.94 0.59 1.51 1.78 1.14 2.80 1.89 1.18 3.01 0.001
Transfat, % total fatty acids
Range < 5.2 5.2-5.9 5.9-6.7 6.7-7.7 > = 7.7
Median 4.6 5.5 6.3 7.2 8.7
Control 195 197 194 197 196 < .0001
Cases 147 147 178 222 303
Model 1 1 0.99 0.73 1.34 1.23 0.91 1.65 1.50 1.12 2.00 2.05 1.55 2.72 < .0001
Model 2 1 0.88 0.56 1.37 1.18 0.77 1.83 1.81 1.20 2.75 1.68 1.11 2.53 0.0003
Model 3 1 0.81 0.51 1.29 1.09 0.69 1.72 1.65 1.07 2.54 1.53 0.99 2.35 0.002
N-6 fatty acids, % total fatty acids
Range < 28.7 28.7-31.1 31.1-33.3 33.3-35.8 > = 35.8
Median 26.4 29.9 32.2 34.4 37.4
Control 195 196 196 196 196 < .0001
Cases 363 225 181 159 70
Model 1 1 0.62 0.48 0.80 0.50 0.38 0.65 0.43 0.33 0.57 0.19 0.14 0.27 < .0001
Model 2 1 0.83 0.57 1.21 0.65 0.44 0.96 0.55 0.38 0.82 0.31 0.20 0.49 < .0001
Model 3 1 0.84 0.57 1.24 0.69 0.46 1.04 0.64 0.42 0.97 0.36 0.22 0.59 < .0001
EPA, % total fatty acids < .0001
Range < 0.28 0.28-0.38 0.38-0.52 0.52-0.76 > = 0.76
Median 0.22 0.33 0.44 0.62 0.94
Control 196 196 196 196 195
Cases 299 186 185 186 142
Model 1 1 0.62 0.47 0.81 0.60 0.46 0.79 0.60 0.45 0.78 0.46 0.34 0.61 < .0001
Model 2 1 0.61 0.41 0.92 0.51 0.34 0.76 0.67 0.45 0.99 0.51 0.33 0.77 0.013
Model 3 1 0.60 0.39 0.91 0.51 0.34 0.78 0.68 0.45 1.03 0.51 0.33 0.80 0.028
DHA, % total fatty acids
Range < 1.97 1.97-2.45 2.45-2.89 2.89-3.56 > = 3.56
Median 1.6 2.2 2.7 3.2 4.0
Control 96 196 195 197 195
Cases 281 256 167 161 133
Model 1 1 0.89 0.69 1.16 0.58 0.44 0.77 0.55 0.42 0.73 0.45 0.34 0.60 < .0001
Model 2 1 0.97 0.66 1.43 0.68 0.45 1.02 0.54 0.36 0.82 0.58 0.38 0.89 0.001
Model 3 1 0.90 0.60 1.34 0.69 0.45 1.05 0.55 0.35 0.85 0.59 0.38 0.92 0.003
Model 1: adjusted for age and gender.
Model 2: additional body mass index, smoking, drinking and exercise.
Model 3: additional LDL cholesterol, systolic and diastolic blood pressure, uric acid, fasting glucose levels and total fat amount in plasma.
Abbreviations see Table 1.
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instead of just one specific fatty acid, extended the
understanding of the role of fatty acids on the risk of
metabolic syndrome. After considering other fatty acids,
DHA and EPA still played an important role for redu-
cing the risk of metabolic syndrome status. The inverse
relationship between marine n-3 fatty acids and meta-
bolic syndrome may implicate the protective effect of
n-3 PUFAs intake in isocaloric substitution for other
fats on metabolic syndrome, which was associated with
the increased risk of cardiovascular diseases [14]. Obser-
vational studies and clinical trials have shown that
intake of EPA and DHA was associated to lower the
cardiovascular risk [11]. The effects of n-3 fatty acids
metabolic syndrome on cardiovascular disease were
mediated through reducing some intermediate markers,
such as metabolic syndrome components and inflamma-
tory biomarkers [15]. The protective roles of EPA and
DHA for the risk of metabolic syndrome might provide
the early prevention of cardiovascular events. Our study
clearly demonstrated the additional beneficial effects of
EPA and DHA for the risk of the metabolic syndrome.
Study strength and limitations
To the best of our knowledge, this study was one of the
few studies to examine the cumulative effects of fatty
acids on the risk of metabolic syndrome. The study
sample size was relatively large and the characteristics of
the study participants were homogeneous; so the results
were internally consistent. However, several limitations
should be mentioned. First, the fatty acids were only
measured once, and variations due to the seasonal avail-
ability of foods were not evaluated. However, the non-
differential misclassification due to measurement would
underestimate the true effect. We believe the true asso-
ciation between fatty acids and the risk of metabolic
s y n d r o m em a yb em o r es i g n i f i c a n t .S e c o n d ,w ed i dn o t
collect the dietary habits in this study. However,
biochemical measurements of fatty acids have a reason-
able validity with the information from food frequency
questionnaires [16,17].
Conclusion
In conclusion, plasma fatty acid concentrations
improved the prediction of the risk of metabolic syn-
drome. Additional joint effects were also found between
two fatty acid levels. Among them, n-6 fatty acid and
marine derived n-3 fatty acids, i.e., EPA and DHA, were
protective factors for the ri s ko fm e t a b o l i cs y n d r o m e .
Further studies on the mechanism of various fatty acids
on the pathway of metabolic syndrome are warranted.
Methods
Study design and population
The study design was a nested case-control study design
based on 8,911 adult participants who were recruited
from the Health Management Center of one tertiary
hospital from January 2004 to December 2007. All parti-
cipants provided written informed consent with the
study protocol being reported elsewhere [18-20]. In
brief, details of socioeconomic status, along with medical
and medication histories were collected by question-
naires, and standardized clinical procedures were
Table 3 Area under the ROC curves comparison with the
base model
AUC 95% CI AUC 95% CI
Base model 0.926 0.915 0.936
Additional for:
Continuous variables * Quintile variables **
Saturated fat, % fat 0.926 0.915 0.937 0.927 0.916 0.937
MUFA, % fat 0.927 0.916 0.937 0.928 0.917 0.939
Transfat, % fat 0.926 0.915 0.937 0.927 0.917 0.938
N-6 fatty acids, % fat 0.927 0.916 0.938 0.928 0.917 0.938
EPA, % fat 0.926 0.916 0.937 0.927 0.916 0.938
DHA, % fat 0.926 0.916 0.937 0.926 0.915 0.937
* test for 7 models, p = 0.08.
** test for 7 models, p = 0.009.
The base model included: age, gender, body mass index, smoking, drinking
and exercise, LDL cholesterol, systolic and diastolic blood pressure, uric acid,
fasting glucose levels and total fat amount in plasma.
AUC: area under the ROC curve; CI: confidence interval.
Table 4 Performance measures of the models including
various fatty acid levels
NRI,
%
95%
CI
P IDI,
%
95%
CI
P
Quintile variables
Saturated fat, %
fat
2.1 0.0 4.2 0.05 0.2 0.0 0.5 0.036
MUFA, % fat 2.2 -0.4 4.8 0.09 0.7 0.3 1.0 0.0001
Transfat, % fat 1.7 -0.8 4.2 0.17 0.5 0.2 0.9 0.001
N-6 fatty acids, %
fat
1.5 -0.9 3.9 0.22 0.7 0.3 1.0 0.0001
EPA, % fat 1.4 -0.9 3.7 0.24 0.4 0.1 0.7 0.002
DHA, % fat 0.2 -1.5 1.9 0.81 0.2 0.0 0.4 0.046
Continuous variables
Saturated fat, %
fat
0.7 -1.0 2.4 0.42 0.1 -0.1 0.3 0.09
MUFA, % fat 1.4 -0.5 3.3 0.15 0.3 0.1 0.5 0.002
Transfat, % fat 0.3 -1.3 1.9 0.71 0.1 -0.1 0.3 0.08
N-6 fatty acids, %
fat
1.6 -0.7 3.9 0.17 0.5 0.2 0.8 0.001
EPA, % fat 1.7 -0.2 3.6 0.08 0.2 0.0 0.5 0.022
DHA, % fat 1.3 -0.6 3.2 0.18 0.2 0.0 0.4 0.031
NRI cutoff points: 0.1, 0.5, and 0.9.
Abbreviations: MUFA: monounsaturated fatty acid; PUFA: polyunsaturated
fatty acid; EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid; NRI: net
reclassification improvement; IDI: integrated discrimination improvement; CI,
confidence interval.
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rent severe medical diseases such as cancer and heart
failure. The participants signed informed consent forms,
and the protocol was approved by the Institutional
Research Board of the hospital.
Details of the subjects’ medical histories such as medi-
cation, hospitalization and smoking status were included
in the structural questionnaires. Standardized procedures
for the physical examination, such as anthropometric
measures and blood pressure, were performed [18,19].
Blood pressure was measured in a resting position by
trained medical assistants. We defined the lifestyle and
clinical covariates as smoking (current smoker, ever-smo-
ker and never smoker), alcohol intake (regular/no), occu-
pation (business and service work), regular exercise (yes/
no), family history of coronary heart disease (yes/no),
baseline hypertension (yes/no, defined by a blood pres-
sure of at least 140/90 mm Hg or on medication), and
diabetes mellitus (yes/no, defined by a fasting plasma glu-
cose of at least 126 mg/dl or on medication).
Blood sampling and analytic methods
The procedures for blood sampling and analytic meth-
ods have been described in previous studies [18,21]. In
brief, blood samples were collected from each partici-
pant after fasting for at least 12 hours. Serum total cho-
lesterol levels were measured using the CHOD-PAP
method (Boehringer Mannheim, Germany). HDL-C was
measured following precipitation of apolipoprotein
B-containing lipoproteins with phosphotungstic acid and
magnesium ions (Boehringer Mannheim, Germany).
Triglyceride concentrations were measured by the GPO-
DAOS method (Wako Co., Japan). All of the lipids were
measured using a Hitachi 7450 automated analyzer
(Hitachi, Japan). LDL-C concentrations were calculated
using the Friedewald formula. Plasma fasting glucose
and 2-hr postprandial glucose concentrations were mea-
sured using a Hitachi 7450 automated analyzer (Hitachi,
Japan). HbA1c levels were measured using a DCA 2000
Table 5 Combination of two fatty acids adjusted confounding factor in multivariable adjusted models
Fatty Acid 1 Fatty Acid 2
Model Marker Odds ratio 95% CI P trend Marker Odds ratio 95% CI P trend
1 EPA, % fat 0.55 0.35 0.86 0.039 Saturated fat, % fat 1.56 1.00 2.45 0.035
2 EPA, % fat 0.49 0.31 0.76 0.027 MUFA, % fat 2.07 1.29 3.32 0.001
3 EPA, % fat 0.52 0.33 0.81 0.057 Transfat, % fat 1.38 0.89 2.14 0.004
4 EPA, % fat 0.48 0.31 0.76 0.012 N-6 fatty acids, % fat 0.36 0.22 0.59 < .0001
5 EPA, % fat 0.63 0.38 1.06 0.43 DHA, % fat 0.72 0.42 1.21 0.033
6 DHA, % fat 0.65 0.39 1.09 0.036 Saturated fat, % fat 1.28 0.77 2.12 0.41
7 DHA, % fat 0.37 0.23 0.61 < .0001 MUFA, % fat 3.01 1.81 5.02 < .0001
8 DHA, % fat 0.72 0.43 1.19 0.10 Transfat, % fat 1.23 0.75 2.01 0.06
9 DHA, % fat 0.73 0.45 1.16 0.076 N-6 fatty acids, % fat 0.41 0.25 0.69 0.001
10 N-6 fatty acids, % fat 0.22 0.11 0.46 0.000 Saturated fat, % fat 0.60 0.30 1.17 0.17
11 N-6 fatty acids, % fat 0.24 0.14 0.41 < .0001 MUFA, % fat 3.02 1.82 5.02 < .0001
12 N-6 fatty acids, % fat 0.33 0.16 0.68 0.008 Transfat, % fat 0.78 0.41 1.50 0.88
13 Transfat, % fat 1.63 0.90 2.92 0.032 Saturated fat, % fat 1.00 0.54 1.84 0.99
14 Transfat, % fat 2.98 1.82 4.90 < .0001 MUFA, % fat 4.11 2.37 7.11 < .0001
15 MUFA, % fat 9.25 4.68 18.3 < .0001 Saturated fat, % fat 7.77 4.14 14.6 < .0001
Abbreviations as for Table 1.
Results are from separate models of each combination of fatty acid profiles. Odds ratios and 95% confidence intervals in the highest compared with the lowest
quintile of each fatty acid. P for trend across quintiles of each profile, and each fatty acid profile was added to the model in quintile with 4 dummy variables.
Adjusted for age, gender, BMI, smoking, drinking and exercise, LDL cholesterol, systolic and diastolic blood pressure, uric acid, fasting glucose levels and total fat
amount in plasma.
Figure 1 Odds ratios according to tertiles of EPA and trans fat
concentrations, adjusted for age, gender, BMI, smoking,
drinking and exercise, LDL cholesterol, systolic and diastolic
blood pressure, uric acid, fasting glucose levels and total fat
amount in plasma. Cutoff points for tertiles of EPA were <0.35,
0.35-0.58, and >0.58% fat. Cutoff points for tertiles of transfat were
<5.7, 5.7-7.1, and >7.1% fat.
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measurements were carried out in a single hospital. The
coefficient of variation was 5%.
Case ascertainment and matched control selection
Metabolic syndrome was defined according to the
updated criteria of the Adult Treatment Panel III [22]
and International Diabetes Federation (IDF), which have
been shown to have excellent consistency [18]. We used
the IDF criteria to ascertain the metabolic syndrome
cases as those who had a major component of central
obesity (defined by a waist circumference greater than
90 cm in men and 80 cm in women) and two other
components from the following: 1) blood pressure of at
least 130/85 mmHg or undergoing treatment for hyper-
tension; 2) serum triglycerides of at least 1.7 mmol/L
(150 mg/dL); 3) HDL cholesterol less than 1.0 mmol/L
(40 mg/dL) in men and less than 1.3 mmol/L (50 mg/
dL) in women; and 4) fasting glucose > = 5.5 mmol/L
(100 mg/dL). In all, 1869 individuals (21%) were classi-
fied as having metabolic syndrome. Next, we randomly
selected 1000 of these individuals and then control sub-
jects were frequency-matched according to age and
gender.
Fatty acid profile measurements in gas chromatography
A 10-ml tube of EDTA-anticoagulated blood was col-
lected, refrigerated at the site centers, and sent back
within 3 hours to the National Taiwan University Hos-
pital core laboratory. The blood was centrifuged at 800
× g for 10 min, then plasma was separated and dis-
pensed into several aliquots and frozen at -70°C for ana-
lysis for fatty acid content by a single technician. After
thawing, 0.5 mL of plasma was extracted with 0.5 mL
methanol followed by 1.0 mL chloroform under a nitro-
gen atmosphere, and the lipid extract was filtered to
remove protein. The methyl esters were then separated
and measured on a 5890 gas chromatograph (Hewlett
Packard, Avondale, PA) equipped with a 30m-FFAT
WCOT glass capillary column (J & W Scientific, Fol-
som, CA) and a flame-ionization detector. The identities
of 29 individual fatty acid peaks were ascertained by
comparing each peak’s retention time relative to the
retention times of FAs of synthetic standards of known
FA components. The relative amount of each FA (% of
total FAs) was quantified by integrating the area under
the peak, and dividing the result by the total area for all
FAs. To minimize transcription errors, the data from
the gas chromatogram was electronically transferred to
a computer for data analysis.
Statistical analysis
All data were presented as mean and standard deviation
for continuous variables and contingency tables for
categorical data, and were listed by status of case
patients and control subjects. The age and gender
adjusted Spearman correlation coefficients were exam-
ined. To compare different fatty acids in predicting the
risk of metabolic syndrome, we used the following
strategies:
First, the frequency of each fatty acid in cases and
controls was calculated and stratified by fatty acid quin-
tiles. We analyzed the association between various fatty
acids and the risk of metabolic syndrome using the
logistic regression model, adjusting for potential con-
founding factors. We specifie dt h r e el o g i s t i cm o d e l st o
evaluate the adjusted odds ratios of quintile values.
Model 1 was adjusted for age (continuous variable) and
gender only. Model 2 included additional body mass
index (continuous variable), smoking, alcohol intake and
exercise status. Model 3 included additional continuous
LDL cholesterol, systolic and diastolic blood pressure,
uric acid, fasting glucose levels and total fat amount in
plasma. To test for linear trends across fatty acid cate-
gories, we used the median fatty acid profile levels
within quintiles as a continuous variable. We also tested
the goodness of fit of the model using the Hosmer and
Lemeshow test [23], and the model fit was acceptable.
Second, we compared the performance of the models
with and without fatty acid measurements using the
area under the receiver operating characteristic curve
(AUC). The curve is a graph of sensitivity versus 1-spe-
cificity (or false-positive rate) for various cutoff defini-
tions of a positive diagnostic test result [24]. Statistical
differences in the AUCs were compared using the
method of DeLong et al. [25], and the difference of
AUC was used to compare the discriminatory capability
among the models.
Third, we provided several additional statistics, includ-
ing integrated discrimination improvement (IDI) and net
reclassification improvement (NRI) [26] for the compari-
son of nested models with and without fatty acids,
because the AUC value is not the best discriminatory sta-
tistic for prediction power [26-28]. In brief, NRI was
based on the reclassification tables and was calculated
from a sum of differences between the ‘upward’ move-
ment in categories for event subjects and the “downward’
movement in those for nonevent subjects [26]. A priori
risk categories were defined according to the a priori risk
categories of stroke (0-10%, 10-50%, 50-90%, and > =
90%), and the reclassification tables according to the
metabolic syndrome were specified. The IDI is consid-
ered to be the difference between improvement in aver-
age sensitivity and any potential increase in average ‘one
minus specificity’ [26], and is estimated as the difference
in Yates discrimination slopes between the nested models
[29,30]. The reclassification table as a tool for comparing
models was suggested by Ridker and colleagues [28].
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Page 7 of 9All statistical analyses were performed using SAS ver-
sion 9.1 (SAS Institute, Inc., Cary, NC) and STATA ver-
sion 9.1 (Stata Corp., College Station, Texas).
Additional material
Additional file 1: Additional Tables S1-S3. Including supplementary
tables for Spearman partial correlation coefficients, Adjusted odds ratios
and 95% confidence intervals for fatty acid concentrations, specified by
continuous variables, and Net reclassification tables.
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